You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance I (MP45)1 Sep 2021MP45-17 ONCOLOGICAL OUTCOMES IN UNCLASSIFIED RENAL CELL CARCINOMA Guilherme Sawczyn, Gilberto Rodrigues, Maykon Pereira, Leonardo Cardilli, Paulo Afonso Carvalho, Fabio Gallucci, Álvaro Sarkis, William Nahas, and Mauricio Cordeiro Guilherme SawczynGuilherme Sawczyn More articles by this author , Gilberto RodriguesGilberto Rodrigues More articles by this author , Maykon PereiraMaykon Pereira More articles by this author , Leonardo CardilliLeonardo Cardilli More articles by this author , Paulo Afonso CarvalhoPaulo Afonso Carvalho More articles by this author , Fabio GallucciFabio Gallucci More articles by this author , Álvaro SarkisÁlvaro Sarkis More articles by this author , William NahasWilliam Nahas More articles by this author , and Mauricio CordeiroMauricio Cordeiro More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002066.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Unclassified renal cell carcinoma (uRCC) is not a distinct subtype of renal cell carcinoma (RCC) but a category that comprises tumors that do not fit any of the RCC subtypes.The aim of this study is to evaluate the influence of histopathological finding of uRCC on oncological outcomes, comparing to clear renal cell carcinoma RCC (ccRCC). METHODS: From July 2011 to August 2019, all ccRCC and uRCC were identified on histopathological database and included. uRCC cases were revised by an experienced uropathologist and reclassified according to the 2016 WHO classification. Baseline characteristics, clinical findings and oncological outcomes were compared between groups. Survival analysis was estimated using the Kaplan-Meier method and compared using log-rank tests. RESULTS: In the period, 74 (9,7%)%) uRCC and 688 (90,3%) ccRCC underwent partial or radical nephrectomy. After pathology review, 26 uRCC cases were reclassified and dismissed. Forty-eight (6,3%) cases remained unclassified. uRCC patients (n=48) were more likely to clinically present with lymphadenomegaly (32.6% vs 15.8%, p=0.0068) and liver metastasis (8.9% vs 2.8%, p=0.049). Histological analysis is more likely to present with a Fuhrman grade 3 or 4 for uRCC (82.9 % vs 53.7 %, p = 0.003) and a higher sarcomatoid / rhabdoid differentiation (20% vs 6.6%, p=0.01) (Table 1). Comparing with high grade ccRCC(Fuhrman grade 3 and 4) and low grade (Fuhrman grade 1 and 2), the estimated recurrence free survival at 48 months was 94.3% for uRCC, 92.5% for ccRCC low grade tumor (p=0.912) and 66.5% for ccRCC high grade tumor (p=0.0055). The estimated overall survival at 48 months was 66.1% for uRCC, 87.4% for ccRCC low grade (p = 0.75) and 63.4% for ccRCC high grade (p<0.0001) (Figure 1). CONCLUSIONS: uRCC is associated with a higher lymphadenegomegaly incidence, a higher sarcomatoid / rhabdoid differentiation and a higher Furhman grade at pathology analysis. uRCC has similar recurrence rate as ccRCC low grade tumor and comparable overall survival rate to ccRCC high grade tumor. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e810-e811 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Guilherme Sawczyn More articles by this author Gilberto Rodrigues More articles by this author Maykon Pereira More articles by this author Leonardo Cardilli More articles by this author Paulo Afonso Carvalho More articles by this author Fabio Gallucci More articles by this author Álvaro Sarkis More articles by this author William Nahas More articles by this author Mauricio Cordeiro More articles by this author Expand All Advertisement Loading ...